Gritstone Oncology (NASDAQ: GRTS) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Gritstone Oncology to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
This is a summary of current recommendations and price targets for Gritstone Oncology and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Gritstone Oncology Competitors||835||2777||6062||261||2.58|
Gritstone Oncology presently has a consensus price target of $22.20, suggesting a potential upside of 51.43%. As a group, “Biological products, except diagnostic” companies have a potential upside of 34.36%. Given Gritstone Oncology’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Gritstone Oncology is more favorable than its peers.
This table compares Gritstone Oncology and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gritstone Oncology Competitors||-5,144.22%||-64.24%||-27.96%|
Institutional and Insider Ownership
59.0% of Gritstone Oncology shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Gritstone Oncology and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Gritstone Oncology||$1.19 million||-$64.78 million||-2.02|
|Gritstone Oncology Competitors||$897.63 million||$190.37 million||-1.35|
Gritstone Oncology’s peers have higher revenue and earnings than Gritstone Oncology. Gritstone Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Gritstone Oncology beats its peers on 7 of the 11 factors compared.
Gritstone Oncology Company Profile
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.